Copyright © 2017 ALM Media Properties, LLC. All Rights Reserved.
Imagine this scenario: You are in-house head IP counsel of an up-and-coming drug company. You have impressed the CEO by securing several issued US patents that provide protection around the company’s lead drug candidate. And then it hits you — none of the claims in the issued patents exactly cover the lead drug candidate. If no patent applications are pending, is all hope lost for securing a patent claim that precisely covers the company’s anticipated product?